Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 07/29/25
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative InnovationGlobeNewsWire • 07/24/25
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025GlobeNewsWire • 06/26/25
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance OrganizationGlobeNewsWire • 06/24/25
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous PemphigoidZacks Investment Research • 06/20/25
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)GlobeNewsWire • 06/20/25
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoidGlobeNewsWire • 06/20/25
Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offerReuters • 06/16/25
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory studyGlobeNewsWire • 06/15/25
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory TrialGlobeNewsWire • 06/15/25
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference TranscriptSeeking Alpha • 06/09/25